3-[(2-{[(1H-benzimidazol-2-ylmethyl)amino]carbonyl}morpholin-4-yl)sulfonyl]-5-bromo-1H-indole-2-carboxamide | 661469-36-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 3-[(2-{[(1H-benzimidazol-2-ylmethyl)amino]carbonyl}morpholin-4-yl)sulfonyl]-5-bromo-1H-indole-2-carboxamide
• 英文别名: 2-({[(4-{[2-(Aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl}morpholin-2-yl)carbonyl]amino}methyl)-1H-benzimidazole；N-(1H-benzimidazol-2-ylmethyl)-4-[(5-bromo-2-carbamoyl-1H-indol-3-yl)sulfonyl]morpholine-2-carboxamide
• CAS: 661469-36-9
• 化学式: C₂₂H₂₁BrN₆O₅S
• 分子量: 561.416
• InChiKey: IPEWLENLQPVAES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  172
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Combination therapy
  申请人：——

  公开号：US20040102360A1

  公开（公告）日：2004-05-27

  The present invention relates to methods of treating cancer using a combination of at least two Akt inhibitors or a compound which is an inhibitor of Akt and an inhibitor of a protein kinase, which methods comprise administering to a mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound(s) which are inhibitors of Akt and compound(s) which are inhibitors of protein kinases. The invention also relates to methods of preparing such compositions.

  本发明涉及使用至少两种Akt抑制剂的组合或一种同时是Akt抑制剂和蛋白激酶抑制剂的化合物来治疗癌症的方法，该方法包括向哺乳动物施用来自以下组合中选择的至少两种治疗剂的量，该组合包括Akt抑制剂和蛋白激酶抑制剂。该发明还涉及制备这种组合物的方法。
• Tyrosine kinase inhibitors
  申请人：Dinsmore J. Christopher

  公开号：US20050261496A1

  公开（公告）日：2005-11-24

  The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a sulfonyl indole moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.

  本发明涉及一种能够抑制、调节和/或调控受体型和非受体型酪氨酸激酶信号转导的化合物。本发明的化合物具有包含磺酰基吲哚基团的核心结构。本发明还涉及这些化合物的药学上可接受的盐、水合物和立体异构体。
• TYROSINE KINASE INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP1534695B1

  公开（公告）日：2010-09-29
• US7560546B2
  申请人：——

  公开号：US7560546B2

  公开（公告）日：2009-07-14